Immediate Impact
55 standout
Citing Papers
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
2024 Standout
Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success
2024 Standout
Works of Sandro Anchisi being referenced
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
2015
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Sandro Anchisi | 406 | 151 | 171 | 48 | 516 | |
| Fabrizio Nelli | 319 | 93 | 351 | 56 | 568 | |
| Tommaso Perretta | 131 | 113 | 116 | 44 | 548 | |
| Francesco Verderame | 350 | 106 | 239 | 50 | 507 | |
| Rita Compagna | 108 | 408 | 126 | 57 | 649 | |
| Biren Parikh | 260 | 196 | 129 | 33 | 555 | |
| Henry Letocha | 348 | 218 | 235 | 34 | 616 | |
| Mutlu Doğan | 263 | 82 | 122 | 77 | 505 | |
| Nataliya Mar | 262 | 274 | 180 | 60 | 554 | |
| Christina Canil | 310 | 135 | 293 | 38 | 578 | |
| Antonio Rueda‐Domínguez | 244 | 80 | 103 | 56 | 560 |
All Works
Login with ORCID to disown or claim papers
Loading papers...